Benefits of Dual I-O Therapy in NSCLC and Malignant Pleural Mesothelioma

Dr Mark Socinski analyzes data from the CITYSCAPE and COAST studies showing improved ORR and PFS with combinations of novel immunotherapy agents in patients with metastatic or locally advanced/unresectable NSCLC, and from the CheckMate-743 study, in which the combination of nivolumab plus ipilimumab resulted in improved survival over chemotherapy in patients with malignant pleural mesothelioma.